Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The classification of colorectal cancer (CRC) by microsatellite instability (MSI) status is important for effective clinical management. In fact, microsatellite instability-high (MSI-H) cancer has distinctive clinicopathological and molecular features. However, microsatellite instability-low (MSI-L) cancer is not clearly defined. The objective of this study was to further clarify the characteristics of MSI-L CRC. A consecutive series of 940 primary CRCs were subdivided into three groups according to the level of MSI and analyzed the clinicopathological features and genetic changes in the KRAS, BRAF and p53 mutation and the loss of heterozygosity (LOH) of adenomatous polyposis coli (APC) gene and methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) and MLH1 promoter. Of the 940 CRCs, 5.9% were MSI-H, 7.1% were MSI-L and 87% were microsatellite stable (MSS). KRAS and BRAF mutations were detected in 39.4 and 4.6% of the CRCs, respectively. The frequency of KRAS mutations in MSI-H, MSI-L and MSS cancer was 30, 48 and 39%, respectively. The proportion of KRAS mutations in MSI-L cancer increased from 16 to 63% accompanying the progression from Dukes' A to Dukes' B. While the LOH of D5S346, which is located near the APC gene, and p53 mutation was observed in 75 and 67% of MSI-L CRC at Dukes' A, respectively. These results indicated that the LOH of APC and p53 mutation has already occurred by the Dukes' A lake 'suppressor pathway' but not the KRAS mutation in MSI-L CRCs. The genes involving MSI-L carcinogenesis are similar to MSS but the timing and frequency of the KRAS mutation is different.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general, it is found in approximately 5% of colorectal cancers [102].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [102]
Citations
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
(2015) · American Journal Of Pathology · doi:10.2353/ajpath · Cited by 4,908
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Microsatellite Instability in Cancer of the Proximal Colon
Thibodeau, S. N., Bren, G., & Schaid, D. (1993) · Science · doi:10.1126/science.8484122 · Cited by 3,130
Ionov, Y., Peinado, M. A., Malkhosyan, S., Shibata, D., & Perucho, M. (1993) · Nature · doi:10.1038/363558a0 · Cited by 2,708
Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer
Leach, F. S., Nicolaides, N. C., Papadopoulos, N., Liu, B., Jen, J., Parsons, R., Peltomäki, P., Sistonen, P., Aaltonen, L. A., Nyström-Lahti, M., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90330-s · Cited by 2,276
Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability
Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., et al. (1995) · Science · doi:10.1126/science.7761852 · Cited by 2,270
Bronner, C. E., Baker, S. M., Morrison, P. T., Warren, G., Smith, L. G., Lescoe, M. K., Kane, M., Earabino, C., Lipford, J., Lindblom, A., et al. (1994) · Nature · doi:10.1038/368258a0 · Cited by 2,052
Genetic instability in colorectal cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/386623a0 · Cited by 1,986
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J.-P. J., Markowitz, S., Willson, J. K. V., Hamilton, S. R., Kinzler, K. W., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6870 · Cited by 1,887
Research works printed but not linked: 14
- Boland, 1998, Cancer Research, 58, 5248
- Risio, 1996, Cancer Research, 56, 5470
- Cunningham, 1998, Cancer Research, 58, 3455
- Halford, 2002, Cancer Research, 62, 53
- Dietmaier, 1997, Cancer Research, 57, 4749
- Parc, 2000, Cancer Research, 60, 2225
- Laiho, 2002, Cancer Research, 62, 1166
- Kambara, 2001, Cancer Research, 61, 7743
- Esteller, 2000, Cancer Research, 60, 2368
- 1996, 111, 307
- Hamelin, 1993, Oncogene, 8, 2213
- 2000, 119, 323
- Esteller, 2001, Cancer Research, 61, 4689
- 1993, 104, 1044
Cited by
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355
Serebriiskii, I. G., Connelly, C., Frampton, G., Newberg, J., Cooke, M., Miller, V., Ali, S., Ross, J. S., Handorf, E., Arora, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11530-0 · Cited by 215
Battaglin, F., Naseem, M., Lenz, H., & Salem, M. E. (2018) · PubMed · Cited by 282
Tong, H., Jiang, Z., Song, L., Tan, K., Yin, X., He, C., Huang, J., Li, X., Jing, X., Yun, H., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.10.019 · Cited by 163
Metadata
- Authors
- Asaka, S.-I., Arai, Y., Nishimura, Y., Yamaguchi, K., Ishikubo, T., Yatsuoka, T., Tanaka, Y., & Akagi, K.
- Affiliations
- Saitama Cancer Center (JP)
- Corresponding author
- Akagi, K.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-09
- Volume
- 30
- Issue
- 3
- Pages
- 494-499
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2140416445
- Cited by
- 76
- References
- 52
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 8 · 2020: 7 · 2019: 7 · 2018: 7 · 2017: 3 · 2016: 8 · 2015: 5 · 2014: 5 · 2013: 1 · 2012: 2
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Carcinogenesis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- KRAS mutation, colorectal cancer progression, BRAF mutation, TP53 mutation, MGMT promoter methylation, MLH1 promoter methylation, tumor suppressor pathways, microsatellite instability-high, microsatellite stable colorectal cancer
- MeSH terms
- MutL Protein Homolog 1, Heterozygote, Humans, Mutation, Nuclear Proteins, Promoter Regions, Genetic, Proto-Oncogene Proteins, Colorectal Neoplasms, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), ras Proteins, Loss of Heterozygosity, O(6)-Methylguanine-DNA Methyltransferase, Proto-Oncogene Proteins B-raf, Adaptor Proteins, Signal Transducing, Microsatellite Instability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B. https://app.cochat.ai/papers/10.1093/carcin/bgp017
- The paper
- Asaka, S.-I., Arai, Y., Nishimura, Y., Yamaguchi, K., Ishikubo, T., Yatsuoka, T., Tanaka, Y., & Akagi, K. (2009). Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B. Carcinogenesis. https://doi.org/10.1093/carcin/bgp017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.